Dihexa: The Angiotensin IV Analogue in Cognitive Research

**Disclaimer:** This article is provided for educational and research purposes only. [Dihexa](/research/dihexa-cognitive) (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an experimental research compound that has not been evaluated or approved by the FDA for any therapeutic use. Viking Labs does not sell dihexa. Nothing in this article constitutes medical advice. All references are to published preclinical research.

Introduction

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic hexapeptide analogue of angiotensin IV (Ang IV, the hexapeptide fragment Val-Tyr-Ile-His-Pro-Phe derived from angiotensin II). Developed by Joseph Harding and colleagues at Washington State University, dihexa represents the culmination of a two-decade research program aimed at understanding and exploiting the procognitive properties of the brain renin-angiotensin system (RAS), a signaling axis that operates independently of the cardiovascular RAS and plays a central role in synaptic plasticity, memory formation, and cognitive function.

What has generated exceptional interest in dihexa is the extraordinary potency reported by its developers: in assays measuring hepatocyte growth factor (HGF)-dependent synaptic connectivity, dihexa was found to be approximately 10 million-fold (seven orders of magnitude) more potent than brain-derived neurotrophic factor (BDNF), the canonical neurotrophin supporting synaptic plasticity and neuronal survival. This claim, published by McCoy et al. (2013) in the Journal of Pharmacology and Experimental Therapeutics, positions dihexa as one of the most potent procognitive compounds identified to date, though significant questions remain about the clinical relevance and safety of such potency.

The Brain Renin-Angiotensin System

The renin-angiotensin system is classically associated with cardiovascular and renal physiology, where angiotensin II acts on AT1 and AT2 receptors to regulate blood pressure, fluid balance, and aldosterone secretion. However, the brain possesses an independent, locally generated RAS with functions that extend well beyond cardiovascular regulation.

Angiotensin IV (Ang IV) is a metabolite of angiotensin II, generated through sequential aminopeptidase cleavage. Unlike angiotensin II, Ang IV does not significantly activate AT1 or AT2 receptors. Instead, it binds to a distinct receptor initially designated AT4, which was subsequently identified by Albiston et al. (2001) as insulin-regulated aminopeptidase (IRAP, also known as oxytocinase or LNPEP).

IRAP is a type II transmembrane aminopeptidase expressed at high levels in brain regions critical for learning and memory, including the hippocampus, amygdala, and neocortex. It co-localizes with the glucose transporter GLUT4 in intracellular vesicles that are translocated to the cell surface in response to insulin signaling. The current understanding is that Ang IV and related analogues act as competitive inhibitors of IRAP's enzymatic activity, thereby preserving the bioavailability of IRAP substrates that include several neuropeptides involved in memory consolidation (oxytocin, vasopressin, somatostatin, and cholecystokinin).

Early studies demonstrated that intracerebroventricular (ICV) administration of Ang IV enhances spatial memory in rodents, as assessed by the Morris water maze, radial arm maze, and passive avoidance paradigms. These procognitive effects are blocked by co-administration of the AT4 receptor antagonist divalinal-Ang IV, confirming receptor-mediated activity. Braszko et al. (1988) provided some of the earliest evidence for the memory-enhancing effects of angiotensin system peptides.

Dihexa: Design and the HGF/c-Met Hypothesis

While the IRAP inhibition model explains some of Ang IV's procognitive effects, Harding's group at Washington State University proposed an alternative and potentially complementary mechanism centered on the hepatocyte growth factor (HGF)/c-Met signaling pathway.

HGF is a pleiotropic growth factor that signals through the c-Met receptor tyrosine kinase. In the brain, HGF/c-Met signaling promotes neuronal survival, dendritic branching, synaptogenesis, and long-term potentiation (LTP) --- the electrophysiological correlate of learning and memory. HGF levels decline with aging, and reduced HGF/c-Met signaling has been observed in the brains of patients with Alzheimer's disease and other neurodegenerative conditions.

Dihexa was developed through structure-activity relationship (SAR) optimization of the Ang IV scaffold to maximize its ability to potentiate HGF/c-Met signaling. The resulting molecule is a truncated dipeptide analogue with N-terminal hexanoic acid and C-terminal aminohexanoic amide modifications that confer metabolic stability, membrane permeability, and --- critically --- the ability to cross the blood-brain barrier after systemic administration (oral or intraperitoneal). This blood-brain barrier penetration distinguishes dihexa from Ang IV itself, which does not cross the BBB and requires intracerebroventricular administration for central effects.

Mechanistically, Benoist et al. (2012) proposed that dihexa acts as a potentiator of HGF/c-Met dimerization. The compound appears to facilitate the binding of HGF to c-Met and/or stabilize the active dimeric configuration of the receptor, thereby amplifying downstream signaling through the PI3K/Akt and Ras/MAPK pathways. This potentiation mechanism may explain the extraordinary apparent potency: rather than acting as a direct agonist (which would require stoichiometric concentrations), dihexa amplifies the effect of endogenous HGF, allowing sub-picomolar concentrations of the peptide to produce measurable biological effects.

Preclinical Evidence: Cognitive Enhancement

The primary preclinical evidence for dihexa's procognitive effects comes from studies conducted by Harding's group using aged rats and scopolamine-impaired rat models.

McCoy et al. (2013) demonstrated that dihexa, administered either intraperitoneally (IP) or orally, enhanced spatial learning and memory in aged rats (24 months old) with established cognitive deficits. In the Morris water maze, aged rats treated with dihexa showed acquisition curves and probe trial performance comparable to young adult rats, while vehicle-treated aged controls showed the expected age-related learning impairment. The doses required were remarkably low: sub-milligram-per-kilogram doses produced maximal effects.

In the scopolamine impairment model (where the muscarinic antagonist scopolamine is used to pharmacologically induce a cholinergic deficit resembling early Alzheimer's disease), dihexa reversed the scopolamine-induced learning deficit across multiple behavioral paradigms.

At the cellular level, dihexa treatment increased dendritic spine density and synaptic connectivity in hippocampal neurons, as assessed by Golgi staining and electrophysiological recordings. The compound enhanced LTP in hippocampal slice preparations from aged rats, restoring the magnitude and duration of potentiation to levels observed in young adult tissue. These synaptic effects correlated with increased phosphorylation of c-Met, Akt, and ERK in hippocampal tissue from dihexa-treated animals, consistent with the proposed HGF/c-Met potentiation mechanism.

Importantly, the procognitive effects of dihexa were blocked by the c-Met inhibitor SU11274, providing pharmacological evidence that HGF/c-Met signaling is necessary for dihexa's cognitive-enhancing activity. Similarly, treatment with anti-HGF antibodies that neutralize the endogenous growth factor abolished dihexa's effects, confirming that the peptide requires endogenous HGF as a co-factor rather than acting as a standalone agonist.

Blood-Brain Barrier Penetration

One of dihexa's most notable pharmacological properties is its ability to cross the blood-brain barrier after systemic administration. This is unusual for a peptide-like molecule and reflects deliberate structural optimization during the SAR process.

Dihexa's ability to cross the BBB is attributed to its small size (molecular weight ~587 Da), lipophilic character (conferred by the hexanoic acid and aminohexanoic amide modifications), and resistance to P-glycoprotein efflux. Pharmacokinetic studies in rats demonstrated measurable brain concentrations following IP or oral administration, with brain-to-plasma ratios suggesting active transport rather than simple passive diffusion.

Comparison to Other Procognitive Approaches

Dihexa occupies a unique mechanistic niche among procognitive agents. Most approved cognitive enhancers (donepezil, rivastigmine, galantamine) act by inhibiting acetylcholinesterase to increase cholinergic transmission, while memantine is an NMDA receptor antagonist. These agents provide symptomatic relief but do not address the underlying neurodegenerative process.

BDNF, the natural neurotrophin most closely associated with synaptic plasticity, does not cross the blood-brain barrier and has a very short half-life in circulation, making it unsuitable for systemic administration. Various strategies to increase brain BDNF levels (exercise, certain antidepressants, TrkB agonists) are under investigation but lack the potency and specificity of direct neurotrophic support.

Dihexa's advantage is the combination of BBB penetration, oral bioavailability, extraordinary potency, and a defined molecular mechanism (HGF/c-Met potentiation) that targets synaptic connectivity rather than neurotransmitter levels. Its limitation is that all published data come from a single research group, and independent replication by other laboratories is limited.

Safety Considerations and Open Questions

The potency of dihexa raises important safety questions. c-Met is an established oncogene, and the theoretical oncogenic potential of chronic HGF/c-Met pathway augmentation requires rigorous evaluation, including long-term carcinogenicity studies that have not been published. The cardiovascular effects of chronic brain RAS modulation also need characterization.

The absence of independent replication remains the most significant limitation. The extraordinary potency claims, while internally consistent within the Washington State University group's publications, await confirmation by independent laboratories.

Summary

Dihexa is a hexapeptide analogue of angiotensin IV that potentiates HGF/c-Met signaling to promote synaptic connectivity and cognitive function in preclinical models. Its reported potency --- orders of magnitude greater than BDNF --- its oral bioavailability, and its blood-brain barrier penetration make it a compelling research tool for studying the role of HGF/c-Met in neuroplasticity and cognitive aging. However, the absence of independent replication, unknown long-term safety profile, and theoretical oncogenic concerns associated with c-Met pathway augmentation represent substantial barriers to clinical translation.

*This article is provided for informational and research purposes only. Viking Labs does not sell dihexa. Nothing in this article should be construed as medical advice.*